Provided by Tiger Trade Technology Pte. Ltd.

Ecopetrol SA

16.67
+0.17001.03%
Post-market: 16.670.00000.00%19:30 EDT
Volume:2.89M
Turnover:48.15M
Market Cap:34.27B
PE:8.76
High:17.15
Open:16.98
Low:16.49
Close:16.50
52wk High:18.19
52wk Low:8.57
Shares:2.06B
Float Shares:237.00M
Volume Ratio:1.98
T/O Rate:1.22%
Dividend:0.99
Dividend Rate:5.94%
EPS(TTM):1.90
EPS(LYR):1.16
ROE:15.95%
ROA:7.31%
PB:1.67
PE(LYR):14.31

Loading ...

EC World REIT faces final court ruling on Fuyang Futoufa guarantees

TIPRANKS
·
May 08

Press Release: Pharming Group reports first quarter 2026 financial results; on track for Joenja(R) U.S. pediatric label expansion and launches in Japan and Europe in 2026

Dow Jones
·
May 07

Moody’s downgrades Ecopetrol’s global credit rating to Ba2

TIPRANKS
·
May 07

Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference

GlobeNewswire
·
May 06

Royalty Pharma reports first quarter 2026 results

GlobeNewswire
·
May 06

UBS Sticks to Its Hold Rating for Ecopetrol SA (EC)

TIPRANKS
·
May 06

Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire
·
May 06

Ecopetrol Is Maintained at Neutral by UBS

Dow Jones
·
May 06

Ecopetrol price target raised to $13.50 from $10 at UBS

TIPRANKS
·
May 05

UBS Adjusts Price Target on Ecopetrol to $13.50 From $10, Maintains Neutral Rating

MT Newswires Live
·
May 05

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

GlobeNewswire
·
May 05

Earning Preview: Ecopetrol SA Q1 revenue is expected to decrease by 3.14%, and institutional views are cautious

Earnings Agent
·
May 05

Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society

GlobeNewswire
·
May 04

Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity

GlobeNewswire
·
May 01

Press Release: Ecopetrol Files Its Form 20-F for the Fiscal Year 2025 with the U.S. Securities and Exchange Commission

Dow Jones
·
May 01

Ecopetrol price target raised to $11 from $9.50 at JPMorgan

TIPRANKS
·
Apr 30

Press Release: Santhera Proposes Dr. Srishti Gupta as New Member of the Board of Directors

Dow Jones
·
Apr 30

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

GlobeNewswire
·
Apr 29

Regeneron Reports First Quarter 2026 Financial and Operating Results

GlobeNewswire
·
Apr 29

Creating a Sustainable Impact: Fosun International Releases 2025 ESG Report and Climate Information Disclosures Report

prnewswire
·
Apr 28